Chad Glasser, PharmD, MPH

Senior Director, Clinical Research

Chad Glasser, PharmD, MPH, is Senior Director of Clinical Research at Tisento Therapeutics. Chad brings more than 12 years of clinical research experience, having worked on a range of preclinical to late-stage programs spanning infectious disease, oncology, and multiple rare disease therapeutic areas. For the last five years, he has focused on advancing the zagociguat clinical program, first at Cyclerion then through the transition to Tisento. Prior to Cyclerion, Chad was a clinical scientist at Acceleron Pharma (acquired by Merck), and before that, he completed a two-year post-doctoral clinical research fellowship and started his career at Cubist Pharmaceuticals (acquired by Merck).

Chad’s thoughtful, calm, and data-driven approach to problem-solving allows him to overcome the complex and seemingly insurmountable challenges of rare disease drug development. Within each stakeholder relationship, whether it be a physician, a regulator, or a patient advocate, Chad strives to maintain the highest degree of credibility and authenticity, with the goal of establishing meaningful and long-lasting collaborations.  

Outside of work, you can find Chad at a recently opened restaurant or cooking a meal that he wishes his two young boys would actually try. 

Proudest professional accomplishment: Officially signing off on the PRIZM study protocol, knowing how much it was shaped by the voices of MELAS patients 

Favorite quote: “If we knew what we were doing, it would not be called research, would it?”
― Albert Einstein